Tags : Pruritus

Pharma Regulatory

Chugai’s Nemolizumab Receives the US FDA’s Breakthrough Therapy Designation to

Shots: Nemolizumab is a novel therapy targeting IL-31 receptor A developed utilizing Chugai’s antibody engineering technology ACT-Ig. The 8th BT designation is granted to the Chugai based on P-II clinical study conducted by Galderma and the results were presented at EADV 2019 The BT designation is granted to serious or life-threatening disease therapies demonstrate a […]Read More